Sunesis Pharma grabs $25M royalty deal for experimental cancer drug; FDA grants orphan status to Threshold Pharma;

 @FierceBiotech: Roche readies for approvals of previously snubbed breast cancer drug T-DM1. More | Follow @FierceBiotech

 @JohnCFierce: Oracle acquires ClearTrial--the "cloud" for clinical trial data. More | Follow @JohnCFierce

 @RyanMFierce: Isis is due $25M if the FDA accepts newly submitted NDA for mipomersen. Article | Follow @RyanMFierce

> Sunesis Pharmaceuticals has landed a deal with Royalty Pharma that could bring $25 million under certain terms in exchange for giving Royalty royalties on potential future sales of its lead drug vosaroxin, which is in Phase III trials as a treatment for acute myeloid leukemia. Release

> Shire ($SHPGY) plans to conduct studies to support the benefit of the drug midodrine after U.S. regulators snubbed Chelsea Therapeutics ($CHTP) in its bid to get approval for a potential rival therapy known as Northera. Report

> Sanofi ($SNY) and Isis Pharmaceuticals ($ISIS) have submitted an application for FDA approval of their drug mipomersen for homozygous familial hypercholesterolaemia (HoFH), and Isis is due a $25 million fee if U.S. regulators accept the application for review. Item

> Shares of Threshold Pharmaceuticals ($THLD) got a boost after the South San Francisco-based drug developer reported that the FDA has granted orphan status for its experimental treatment TH-302 for combating rare cancer called soft tissue sarcoma. Article

> U.S. biotech NGM Biopharmaceuticals has scored a partnership with Japan's Daiichi Sankyo to research new drugs for diabetes. Financial terms were not disclosed. Report

Pharma News

 @FiercePharma: France's drug market to shrink this year. No surprise, given the austerity-related cost cuts. Article | Follow @FiercePharma

> Dendreon's Provenge faces new questions. More

> Bayer gets positive ruling from NICE on Xarelto. News

> North Carolina considers drug liability protections. Story

> France's drug spending will shrink for first time, IMS says. Article

Medical Device News

@FierceMedDev: Europe Weighs Tougher Breast Implant Scrutiny - BusinessWeek. Story | Follow @FierceMedDev

> After 11 malfunctions, St. Jude pulls Brio DBS device. News

> FDA panel to hear experts, patients on metal hips. Story

> Globus files for estimated $100M IPO. Article

> Roche pressures Illumina with higher, $6.7B offer. More

And Finally… Finally, Roche ($RHHBY) has upped its bid to acquire DNA sequencing machine maker Illumina ($ILMN). Details

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.